Pfizer's Paxlovid Covid-19 pill receives FDA adcomm support for high-risk adults.
TL;DR Summary
The FDA's Antimicrobial Drugs Advisory Committee has voted 16-1 in favor of Pfizer's COVID-19 antiviral pill, Paxlovid, for use in adults with mild-to-moderate illness. The FDA is currently reviewing Pfizer's request to convert its EUA to a full approval, with a decision expected in May 2023. If granted full approval, Paxlovid's EUA will remain in place so that adolescents 12 years and older can continue to be treated with the drug.
- FDA adcomm votes in favor of Pfizer's Covid-19 pill Paxlovid Endpoints News
- FDA advisers vote in support of Paxlovid approval for Covid-19 treatment in high-risk adults CNN
- FDA advisors recommend full approval of Pfizer Covid treatment Paxlovid for adults 50 and over and other high-risk people CNBC
- AI-based drug interaction prediction technology analyzes the interaction between Paxlovid ingredients News-Medical.Net
- COVID-19 treatment Paxlovid for high-risk adults close to full FDA approval WKRC TV Cincinnati
Reading Insights
Total Reads
0
Unique Readers
11
Time Saved
8 min
vs 9 min read
Condensed
96%
1,642 → 71 words
Want the full story? Read the original article
Read on Endpoints News